Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol Mebutate Gel for Large Area Actinic Keratosis
NCT02361216Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Ingenol mebutate gel with Vehicle (2 arms). Primary endpoint: Percentage of Participants With Complete Resolution of Actinic Keratosis (AK) at 8 weeks. Started Apr 2015; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02361216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361216.